COYA
Coya Therapeutics
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- The first patient cohort in the ALSTARS trial entered the blinded active-treatment extension phaseJun 8, 2026
- Coya Therapeutics receives FDA Fast Track designation for COYA 302 in ALSMay 12, 2026
- Coya Therapeutics announces FDA acceptance of IND application for COYA 302 to treat frontotemporal dementiaJan 5, 2026
- Coya Therapeutics announces patient dosing in ALSTARS trial of COYA 302 for ALS treatmentDec 9, 2025
- Coya Therapeutics announces completion of patient enrollment for investigator-initiated, open-label study with low-dose IL-2 and CTLA4-Ig combination in mild to moderate frontotemporal dementiaSep 29, 2025